Highest-materiality recent filing
Seven directors elected with votes ranging from 17.3M to 20.0M; broker non-votes 3.1M.
Revenue of $59.9M, up 44.7% YoY; US Motiva sales $19.6M (vs $6.2M Q1 2025).
Establishment Labs enters up to $300M credit facility with Oaktree; repays ~$259M existing debt
Tranche E Term Loan of $265M drawn April 30, 2026; optional Tranche F up to $35M.
Establishment Labs Q4 rev $64.6M (+45% YoY); guides 2026 rev $264-266M
Full year 2025 revenue $211.1M (+27.2% YoY); Q4 net loss $3.9M vs $18.7M loss a year ago.
Presentation at J.P. Morgan conference; no financial updates disclosed
Furnished presentation materials for J.P. Morgan Healthcare Conference on Jan 14, 2026.
Establishment Labs expects Q4 revenue $64M-$65M; FY 2025 up 27% YoY
Q4 2025 revenue expected $64.0M-$65.0M, including $17.0M-$17.5M from Motiva US sales.
Establishment Labs Q3 revenue $53.8M (+33.8% YoY), positive Adj. EBITDA, raises FY guidance
Revenue $53.8M, up 33.8% YoY; US Motiva sales $11.9M.
Establishment Labs amends credit agreement, draws $25M Tranche D term loans
Fourth Amendment allows immediate availability of $25M Tranche D Term Loans, waiving revenue milestone.
Establishment Labs Q2 revenue $51.3M (+16% YoY); raises FY2025 guidance to $208-212M
Revenue $51.3M, up 16.3% YoY; US Motiva sales $10.3M.
Motiva USA update: >1,000 surgeons, Q2 sales guide $9.5-10M, reconstruction filing Q4 2025
Over 1,000 surgeons now offer Motiva implants in the United States.
Shareholders re-elect all director nominees; Bryan Slotkin receives 92% for
All four director nominees elected: Chacón Quirós, Custin, Lewin, Schutter each received >21.4M for; Slotkin 19.9M for, 1.7M against.
Establishment Labs replaces auditor Marcum with CBIZ after acquisition of attest business
Marcum resigned May 20, 2025; Audit Committee appointed CBIZ same day for FY 2025.
Establishment Labs appoints Peter Caldini as permanent CEO, effective May 7, 2025
Caldini had served as interim CEO since March 1, 2025, following founder Juan José Chacón-Quirós's retirement.
Establishment Labs Q1 revenue $41.4M, net loss $20.7M; appoints Peter Caldini CEO
Q1 revenue $41.4M (up from $37.2M YoY); net loss $20.7M vs $16.2M loss in prior year.
Establishment Labs reports preliminary Q1 revenue $41.4M, reiterates 2025 guidance $205-210M
Preliminary Q1 2025 revenue ~$41.4M, including ~$6.2M US Motiva sales.
Establishment Labs Q4 revenue $44.5M; reaffirms 2025 guidance of $205-210M
Q4 revenue $44.5M (+41% YoY); gross margin 68.5% (up from 65.2%).
Establishment Labs guides 2025 revenue $205M-$210M, positive adjusted EBITDA in 2025
2025 revenue guidance of $205M-$210M ($170M-$175M international, $35M US).
Founder CEO Chacón-Quirós to retire March 1; 2024 revenue guidance $166M-$166.5M
CEO Juan José Chacón-Quirós retires effective March 1, 2025; stays on board and as advisor.
Establishment Labs extends Tranche D loan commitment to Dec 2025 and raises ~$49.8M in equity
Amended credit agreement: Tranche D term loan commitment termination date extended to Dec 31, 2025 from June 30, 2025.
Q3 revenue $40.2M vs $38.5M YoY; net loss $16.7M vs $29.3M loss YoY; adjusted EBITDA loss $7.0M vs $16.3M loss.
Offering of 765,696 common shares at $45.71/share and pre-funded warrants for 328,161 shares; total gross proceeds ~$50M.
FDA approves Motiva SmoothSilk implants for breast augmentation; first new PMA since 2013
FDA approval for Motiva SmoothSilk Ergonomix and Round implants in primary and revision breast augmentation.
Appoints Fillipo 'Peter' Caldini as President; base salary $415K, $1M equity grant
Appointed Fillipo 'Peter' Caldini as President effective August 20, 2024, reporting to CEO.
Establishment Labs Q2 revenue $44.1M, loss narrows; FDA PMA inspection completed
Q2 revenue $44.1M vs $48.6M YoY; gross margin improved to 65.6% from 62.3%.
FDA PMA preapproval inspection of Establishment Labs' Motiva Implant facility rescheduled to July 22
FDA will begin PMA preapproval inspection of Motiva Implants manufacturing facility on July 22, 2024.
FDA deems Establishment Labs' Motiva Implants PMA approvable pending facility inspection
FDA CDRH completed PMA review for Motiva Implants; says PMA is approvable subject to acceptable manufacturing facility inspection.
Establishment Labs shareholders elect directors, approve say-on-pay, ratify auditor
Ann Custin received 18,049,023 votes for, 1,659,450 against; Bryan Slotkin 18,175,945 for, 1,532,799 against.
Q1 2024 revenue $37.2M (down 20% YoY from $46.5M); net loss $16.2M vs $11.9M loss in Q1 2023.
FDA schedules PMA preapproval inspection of Establishment Labs' Motiva Implants facility in Q2 2024
FDA schedules PMA preapproval inspection of Motiva Implants manufacturing facility for Q2 2024.
appointed the Company’s interim Chief Executive Officer Fillipo “Peter” Caldini to serve as Chief Executive Officer, effective May 7, 2025.
The Board also appointed Mr. Caldini as a Class II director of the Company, effective May 24, 2025.
Fillipo “Peter” Caldini, the Company’s current President, will serve as Interim CEO as of March 1, 2025.
Juan José Chacón-Quirós, the Company’s Chief Executive Officer, has provided notice of his decision to retire from his position as Chief Executive Officer, effective on March 1, 2025.
On August 20, 2024, the Board of Directors of Establishment Labs Holdings Inc. (the “Company”) appointed Fillipo “Peter” Caldini to the position of President of the Company effective immediately (the “Start Date”).
Max materiality 0.85 · Median 0.70 · Most common event earnings